Legislature(2005 - 2006)BUTROVICH 205
05/04/2005 01:30 PM Senate HEALTH, EDUCATION & SOCIAL SERVICES
| Audio | Topic |
|---|---|
| Start | |
| HB214 | |
| HJR20 | |
| HB53 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| += | HB 214 | TELECONFERENCED | |
| + | HJR 20 | TELECONFERENCED | |
| += | HB 53 | TELECONFERENCED | |
| + | TELECONFERENCED |
HJR 20-PROSTATE CANCER DRUGS
CHAIR DYSON announced HJR 20 to be up for consideration.
CODY RICE, staff to Representative Carl Gatto, sponsor, said:
HJR 20 essentially recognizes the fact that there are
currently no targeted, as they are called, therapies
for prostate cancer. There are specifically targeted
drug therapies that is for other specific types of
cancer. And this resolution would urge Congress and
the FDA to expedite where possible the approval of
such targeted therapies.
CHAIR DYSON asked if the FDA and Congress are currently failing
to expedite the approval of these drugs.
MR. RICE replied that there are currently no approved drugs for
prostate cancer, although some such drugs that are in the later
stages of approval for what is called "end of life care" or
"compassionate use" and drugs have been approved for the end-of-
life-care of patients with AIDS and some forms of cancer.
2:23:32 PM
CHAIR DYSON asked if it is fair to say that Xinlay, on page 2,
line 6, is an explicit request in the midst of a general
request.
MR. RICE replied:
Yes, Xinlay, astrasentan, is the only drug that we're
aware of that is specifically targeted for prostate
cancer that has, then, reached the later series of
trials through the FDA. It's my understanding that
there may be one other drug out there and that is why
we left the final be-it-resolved more general....
2:25:11 PM
SENATOR ELTON said that he supports the bill, but he is somewhat
uncomfortable with including the name of a specific drug within
the resolution because he does not want his support of this
resolution to be an endorsement of a drug that he does not
understand or to indicate that he believes there are not other
drugs that should be considered.
2:26:44 PM
SENATOR WILKEN moved to report HJR 20 from committee with
individual recommendations and zero fiscal notes. There were no
objections and it was so ordered.
| Document Name | Date/Time | Subjects |
|---|